Literature DB >> 8105312

Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death.

A J Marian1, Q T Yu, R Workman, G Greve, R Roberts.   

Abstract

We determined the distribution frequency of angiotensin converting enzyme (ACE) polymorphism in 100 patients with hypertrophic cardiomyopathy and 106 of their unaffected siblings and offspring. The distribution of ACE genotypes was different in the two groups: allele D frequency of 0.69 in patients and 0.57 in relatives (p = 0.021). The frequency of allele D was also higher in hypertrophic cardiomyopathy families with a high incidence of sudden cardiac death than those with a low incidence (0.74 vs 0.55, p = 0.011). In 25 hypertrophic cardiomyopathy patients with a strong family history of sudden cardiac death the frequency of allele D was 0.82 (p = 0.001 vs normals).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105312     DOI: 10.1016/0140-6736(93)92064-z

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  71 in total

Review 1.  Molecular genetics of cardiomyopathies.

Authors:  G Shah; R Roberts
Journal:  J Nucl Cardiol       Date:  2000 Mar-Apr       Impact factor: 5.952

2.  On genetic and phenotypic variability of hypertrophic cardiomyopathy: nature versus nurture.

Authors:  A J Marian
Journal:  J Am Coll Cardiol       Date:  2001-08       Impact factor: 24.094

Review 3.  Modifier genes for hypertrophic cardiomyopathy.

Authors:  A J Marian
Journal:  Curr Opin Cardiol       Date:  2002-05       Impact factor: 2.161

Review 4.  Genetics of cardiovascular disease with emphasis on atrial fibrillation.

Authors:  R Brugada; J Brugada; R Roberts
Journal:  J Interv Card Electrophysiol       Date:  1999-03       Impact factor: 1.900

5.  Association of angiotensin converting enzyme and angiotensin II type 1 receptor genotypes with left ventricular function and mass in patients with angiographically normal coronary arteries.

Authors:  M Hamon; C Amant; C Bauters; F Richard; N Helbecque; E McFadden; J M Lablanche; M Bertrand; P Amouyel
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

Review 6.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

Review 7.  A new era in clinical genetic testing for hypertrophic cardiomyopathy.

Authors:  Matthew Wheeler; Aleksandra Pavlovic; Emil DeGoma; Heidi Salisbury; Colleen Brown; Euan A Ashley
Journal:  J Cardiovasc Transl Res       Date:  2009-10-30       Impact factor: 4.132

8.  The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.

Authors:  Martin Penicka; Pavel Gregor; Roman Kerekes; Dan Marek; Karol Curila; Jiri Krupicka
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

Review 9.  Molecular basis of hypertrophic and dilated cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  Tex Heart Inst J       Date:  1994

10.  Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy.

Authors:  H Yoshida; T Mitarai; T Kawamura; T Kitajima; Y Miyazaki; R Nagasawa; Y Kawaguchi; H Kubo; I Ichikawa; O Sakai
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.